Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2021-04-23 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
Management information circular - English.pdf
Regulatory Filings
2021-04-23 English
Code of conduct.pdf
Regulatory Filings
2021-04-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the granting of a U.S. patent for a treatment method related to interstitial cystitis by Tetra Bio-Pharma. It discusses the intellectual property portfolio, the medical condition, and the company's plans for commercialization. There is no financial data, regulatory filing, or report content such as earnings, annual reports, or management discussions. The document is an announcement of a corporate development (patent grant) rather than a financial or regulatory report. Therefore, it does not fit into categories like 10-K, IR, ER, or others related to financial reporting. It is best classified as a Regulatory Filing (RNS) since it is a general corporate announcement that does not fit other specific categories.
2021-04-15 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO of Tetra Bio-Pharma Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended February 28, 2021. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, including controls and procedures. It does not contain the actual interim financial statements or substantive financial data itself, but rather attests to their validity. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself.
2021-04-15 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO of Tetra Bio-Pharma Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended February 28, 2021. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3860 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2021-04-15 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management's Discussion and Analysis' (MD&A) for the three months ended February 28, 2021. It contains detailed discussion of financial results, business overview, risk factors, and forward-looking statements. It references interim financial statements and is prepared according to IFRS. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content and structure align with a comprehensive interim or quarterly report rather than a simple earnings release or regulatory filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.